Highlights

  • Patrys shares rose 3.12% on 20 May 2026, as investors reacted positively to the latest operational update.
  • Patrys appointed CMAX as the clinical trial site for its Phase 1A RLS-2202 study.
  • Alithia Life Sciences was selected as Contract Research Organisation for trial oversight.
  • The company remains on track for Phase 1A trial initiation in Q3 2026, subject to approvals.
  • The trial will assess safety, tolerability and pharmacokinetics in healthy volunteers.
  • RLS-2202 is being developed as an injectable delirium treatment for acute care settings.

Patrys Limited (ASX:PAB) shares traded higher during the afternoon session on 20 May 2026 after the company announced key appointments supporting the advancement of its RLS-2202 program toward Phase 1 clinical development.

The company confirmed the appointment of CMAX as the Phase 1A clinical trial site and Alithia Life Sciences as the Contract Research Organisation (CRO) responsible for overseeing operational and clinical trial management activities.

Shares of Patrys Limited traded at AUD 0.033, up 3.12% for the day. The stock has also gained approximately 65% over the past year.

Company Overview

Patrys Limited is an ASX-listed biotechnology company developing therapies targeting delirium and immune-mediated inflammatory diseases.

The company’s pipeline includes RLS-2202, an injectable formulation of Quetiapine designed for acute care settings, alongside its deoxymab technology platform.

Patrys is focused on advancing programs through clinical-stage development and regulatory pathways.

Phase 1A Trial Preparations Move Forward

The latest appointments represent another step in Patrys’ progression toward clinical-stage development for RLS-2202, its injectable formulation designed for the treatment of delirium in acute care settings.

According to the company, the upcoming Phase 1A study is intended to evaluate the safety, tolerability and pharmacokinetics (PK) of RLS-2202 in healthy volunteers.

Patrys stated that the appointments complete an important operational milestone for the program, establishing the framework required to move into Phase 1A clinical activities.

The company also noted that the trial remains subject to Human Research Ethics Committee (HREC) approval, with initiation still targeted for Q3 2026.

Investor Focus Turns to Clinical Development Timeline

The market appeared to respond favourably to the update as investors continued monitoring progress across Patrys’ development pipeline.

The appointments follow earlier Manufacturing and regulatory preparation activities announced by the company in March 2026 as it worked toward clinical entry for RLS-2202.

With both the clinical trial site and CRO now selected, Patrys is expected to progress final protocol preparation, ethics submissions and trial initiation activities over the coming months.

The company stated that first participant dosing remains targeted for Q3 CY2026, subject to approvals.

CMAX Selected as Phase 1 Clinical Trial Site

Patrys confirmed that CMAX will serve as the physical site where the Phase 1A trial will be conducted.

CMAX is a specialised Phase 1 clinical unit based in Adelaide and has experience conducting early-stage and first-in-human studies across multiple therapeutic areas.

The company said the appointment provides access to specialist Phase 1 infrastructure, experienced investigators and established participant recruitment capabilities.

Study participants in the upcoming RLS-2202 trial are expected to be dosed and monitored at the CMAX Facility.

Patrys stated that the selection followed a competitive evaluation process focused on operational quality, safety oversight and Phase 1 clinical experience.

Alithia Life Sciences to Oversee Trial Operations

Alongside the CMAX appointment, Alithia Life Sciences has been appointed as CRO for the study.

The CRO role involves coordinating and managing broader operational, regulatory and oversight activities associated with the clinical trial.

According to the company, Alithia will provide services including project management, pharmacovigilance, regulatory coordination, data management, protocol monitoring, vendor oversight and trial administration.

Patrys stated that these activities are intended to support trial execution in accordance with Good Clinical Practice (GCP) and regulatory requirements.

The company also indicated that the CRO appointment is designed to support reliable interpretation of safety, tolerability and pharmacokinetic data generated during the study.

A/Prof Tina Soulis, Founder and Director of Alithia, described the collaboration as an exciting opportunity and said the organisation was pleased to support the progress of an Australian biotechnology company.

Management Commentary on the Program

Patrys Chief Executive Officer Dr Samantha South said the appointments establish an important operational foundation for the company’s clinical-stage development plans.

Management noted that both organisations bring experience in early-stage clinical development and Phase 1 trial execution.

According to Dr South, the company continues progressing RLS-2202 toward first participant dosing while focusing on the unmet need for delirium treatment within acute care environments.

The company reiterated that trial commencement remains on schedule for Q3 CY2026, pending regulatory and ethics approvals.

Understanding the RLS-2202 Program

RLS-2202 is a proprietary injectable formulation of Quetiapine designed for use in acute care settings.

Patrys stated that the formulation is intended to provide rapid, predictable and effective treatment of delirium.

Delirium remains a significant challenge in hospital and acute care settings, particularly among older patients and individuals experiencing severe illness or post-surgical complications.

The company indicated that the RLS-2202 program is expected to pursue the FDA 505(b)(2) regulatory pathway, alongside equivalent international approval routes.

This pathway may allow the company to Leverage existing clinical and safety data associated with Quetiapine while generating additional data specific to the intravenous formulation being developed.

Patrys also noted that RLS-2202 complements the company’s broader deoxymab platform and forms part of its wider development pipeline.

Broader Focus on Clinical and Development Strategy

Patrys Limited continues positioning itself as a clinical-stage biotechnology company with a focus on injectable therapies and immune-mediated inflammatory disease programs.

The company’s development strategy currently includes both the RLS-2202 program and its deoxymab platform technologies.

Biotechnology investors often monitor early-stage companies closely for progress across manufacturing, regulatory and clinical trial milestones, particularly ahead of first-in-human studies.

Phase 1 studies are generally focused on evaluating safety, dosage and pharmacokinetics before broader efficacy-focused development stages.

The latest update indicates that Patrys has now established several of the operational components required to progress the RLS-2202 program toward initial clinical testing.

Next Steps Ahead of Trial Commencement

Patrys stated that upcoming activities will include finalisation of the clinical trial protocol, regulatory submissions and ethics approval processes.

The company also plans to initiate site activities at CMAX ahead of participant dosing.

Further Shareholder updates are expected as regulatory submissions progress and timelines for trial initiation are confirmed.

At this stage, commencement of dosing remains dependent on HREC approval and completion of required regulatory processes.

What This Means for Investors?

Patrys’ latest announcement highlighted continued progress toward Phase 1 clinical development for its RLS-2202 program.

The appointments of CMAX and Alithia establish operational and clinical oversight arrangements ahead of the planned Phase 1A study, while the company remains on track for Q3 2026 trial initiation, subject to approvals.

The market reaction suggests investors are closely watching milestones linked to regulatory preparation, clinical trial execution and advancement of the company’s injectable delirium treatment program.

With Phase 1 preparations progressing, future updates regarding ethics approvals, trial commencement and participant dosing timelines may remain areas of interest for shareholders.